SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corixa [CRXA] - cancer vaccines
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andreas Helke who started this subject11/25/2002 5:11:33 PM
From: sim1  Read Replies (1) of 222
 
ASH Abstract: BEXXAR Produces a Substantial
Number of Durable Complete Responses
Monday November 25, 4:00 pm ET

Abstract #1382 Reports Long-Term Follow-up from BEXXAR
Clinical Trials

SEATTLE--(BUSINESS WIRE)--Nov. 25, 2002--Corixa Corporation (Nasdaq: CRXA -
News) today announced that an abstract reporting results from long-term follow-up on
250 patients from five clinical trials with BEXXAR® (tositumomab and iodine I 131
tositumomab) therapy is available on the web site of the American Society of
Hematology (ASH).

Abstract #1382, Bexxar radioimmunotherapy produces a substantial number of durable
complete responses in patients with multiple relapsed or refractory low grade or
transformed low grade non-Hodgkin's lymphoma (Kaminski MS, Zelenetz A, Leonard J,
et al.), reports that the confirmed complete response (CR) rate was 30 percent and the
median duration of CR has not been reached. Seventy (70) percent of the BEXXAR
therapy patients who achieved a CR are alive today and remain in CR up to 7.8+ years.
Overall confirmed response rate was 56 percent and median duration of response was
14.7 months.

Abstract #1382, as well as other BEXXAR therapy abstracts, are currently available to
the public at hematology.org

BEXXAR therapy, an investigational radioimmunotherapy being studied for the
treatment of relapsed or refractive low-grade or transformed low-grade non-Hodgkin's
lymphoma (NHL), will be presented to the U.S. Food and Drug Administration's
Oncologic Drugs Advisory Committee (ODAC) on December 17.<snip>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News